These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 31475741)

  • 61. Nanoscale flow cytometry to distinguish subpopulations of prostate extracellular vesicles in patient plasma.
    Padda RS; Deng FK; Brett SI; Biggs CN; Durfee PN; Brinker CJ; Williams KC; Leong HS
    Prostate; 2019 May; 79(6):592-603. PubMed ID: 30680751
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [ARV-7: A biomarker for the treatment of metastatic castration-resistant prostate cancer].
    Chen ZY; Dong Q; Liu LR; Wei Q
    Zhonghua Nan Ke Xue; 2019 Feb; 25(2):172-176. PubMed ID: 32216207
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Detection of AR-V7 mRNA in whole blood may not predict the effectiveness of novel endocrine drugs for castration-resistant prostate cancer.
    Takeuchi T; Okuno Y; Hattori-Kato M; Zaitsu M; Mikami K
    Res Rep Urol; 2016; 8():21-5. PubMed ID: 26870716
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer.
    Huang X; Yuan T; Liang M; Du M; Xia S; Dittmar R; Wang D; See W; Costello BA; Quevedo F; Tan W; Nandy D; Bevan GH; Longenbach S; Sun Z; Lu Y; Wang T; Thibodeau SN; Boardman L; Kohli M; Wang L
    Eur Urol; 2015 Jan; 67(1):33-41. PubMed ID: 25129854
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Expression of Androgen Receptor Variant 7 (AR-V7) in Circulated Tumor Cells and Correlation with Drug Resistance of Prostate Cancer Cells.
    Wang S; Yang S; Nan C; Wang Y; He Y; Mu H
    Med Sci Monit; 2018 Oct; 24():7051-7056. PubMed ID: 30284554
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Urinary exosome-based androgen receptor-variant 7 detection in metastatic castration-resistant prostate cancer patients.
    Wang C; Liu X; Li H; Zhao L; Kong G; Chen J; Li Z; Qi J; Tian Y; Zhang F
    Transl Androl Urol; 2022 Feb; 11(2):202-212. PubMed ID: 35280667
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Associations between AR-V7 status in circulating tumour cells, circulating tumour cell count and survival in men with metastatic castration-resistant prostate cancer.
    Belderbos BPS; Sieuwerts AM; Hoop EO; Mostert B; Kraan J; Hamberg P; Van MN; Beaufort CM; Onstenk W; van Soest RJ; Martens J; Sleijfer S; de Wit R; Mathijssen RHJ; Lolkema MP
    Eur J Cancer; 2019 Nov; 121():48-54. PubMed ID: 31542641
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Androgen Receptor Signaling in Castration-Resistant Prostate Cancer Alters Hyperpolarized Pyruvate to Lactate Conversion and Lactate Levels In Vivo.
    Zacharias N; Lee J; Ramachandran S; Shanmugavelandy S; McHenry J; Dutta P; Millward S; Gammon S; Efstathiou E; Troncoso P; Frigo DE; Piwnica-Worms D; Logothetis CJ; Maity SN; Titus MA; Bhattacharya P
    Mol Imaging Biol; 2019 Feb; 21(1):86-94. PubMed ID: 29748904
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Androgen receptor (AR) splice variant 7 and full-length AR expression is associated with clinical outcome: a translational study in patients with castrate-resistant prostate cancer.
    Del Re M; Crucitta S; Sbrana A; Rofi E; Paolieri F; Gianfilippo G; Galli L; Falcone A; Morganti R; Porta C; Efstathiou E; van Schaik R; Jenster G; Danesi R
    BJU Int; 2019 Oct; 124(4):693-700. PubMed ID: 31055861
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance.
    Kohli M; Ho Y; Hillman DW; Van Etten JL; Henzler C; Yang R; Sperger JM; Li Y; Tseng E; Hon T; Clark T; Tan W; Carlson RE; Wang L; Sicotte H; Thai H; Jimenez R; Huang H; Vedell PT; Eckloff BW; Quevedo JF; Pitot HC; Costello BA; Jen J; Wieben ED; Silverstein KAT; Lang JM; Wang L; Dehm SM
    Clin Cancer Res; 2017 Aug; 23(16):4704-4715. PubMed ID: 28473535
    [No Abstract]   [Full Text] [Related]  

  • 71. The characteristics of androgen receptor splice variant 7 in the treatment of hormonal sensitive prostate cancer: a systematic review and meta-analysis.
    Wang Z; Shen H; Liang Z; Mao Y; Wang C; Xie L
    Cancer Cell Int; 2020; 20():149. PubMed ID: 32390764
    [TBL] [Abstract][Full Text] [Related]  

  • 72. mRNA expressions of androgen receptor and its variants in matched hormone-sensitive and castration-resistant prostate cancer.
    Park HK; Lim SD; Kwon GY
    Scand J Urol; 2019 Dec; 53(6):365-371. PubMed ID: 31809622
    [No Abstract]   [Full Text] [Related]  

  • 73. Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease?
    Lohaus F; Zöphel K; Löck S; Wirth M; Kotzerke J; Krause M; Baumann M; Troost EGC; Hölscher T
    Eur Urol; 2019 Apr; 75(4):548-551. PubMed ID: 30578119
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC).
    Welti J; Sharp A; Yuan W; Dolling D; Nava Rodrigues D; Figueiredo I; Gil V; Neeb A; Clarke M; Seed G; Crespo M; Sumanasuriya S; Ning J; Knight E; Francis JC; Hughes A; Halsey WS; Paschalis A; Mani RS; Raj GV; Plymate SR; Carreira S; Boysen G; Chinnaiyan AM; Swain A; de Bono JS;
    Clin Cancer Res; 2018 Jul; 24(13):3149-3162. PubMed ID: 29555663
    [No Abstract]   [Full Text] [Related]  

  • 75. Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer.
    Bernemann C; Schnoeller TJ; Luedeke M; Steinestel K; Boegemann M; Schrader AJ; Steinestel J
    Eur Urol; 2017 Jan; 71(1):1-3. PubMed ID: 27471164
    [TBL] [Abstract][Full Text] [Related]  

  • 76. CTC-derived AR-V7 detection as a prognostic and predictive biomarker in advanced prostate cancer.
    Bastos DA; Antonarakis ES
    Expert Rev Mol Diagn; 2018 Feb; 18(2):155-163. PubMed ID: 29319382
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Role of extracellular vesicles in castration-resistant prostate cancer.
    Liao C; Huang Z; Liu J; Deng M; Wang L; Chen Y; Li J; Zhao J; Luo X; Zhu J; Wu Q; Fu W; Sun B; Zheng J
    Crit Rev Oncol Hematol; 2024 May; 197():104348. PubMed ID: 38588967
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Circulating Tumor Cells as a Marker for Progression-free Survival in Metastatic Castration-naïve Prostate Cancer.
    Josefsson A; Linder A; Flondell Site D; Canesin G; Stiehm A; Anand A; Bjartell A; Damber JE; Welén K
    Prostate; 2017 Jun; 77(8):849-858. PubMed ID: 28295408
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The Role of PCA 3 as a Prognostic Factor in Patients with Castration-resistant Prostate Cancer (CRPC) Treated with Docetaxel.
    Bourdoumis A; Chrisofos M; Stasinou T; Christopoulos P; Mourmouris P; Kostakopoulos A; Deliveliotis C
    Anticancer Res; 2015 May; 35(5):3075-9. PubMed ID: 25964598
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Dual androgen receptor (AR) and STAT3 inhibition by a compound targeting the AR amino-terminal domain.
    Hua Y; Azeem W; Shen Y; Zhang S; Olsen JR; Øyan AM; Ke X; Zhang W; Kalland KH
    Pharmacol Res Perspect; 2018 Dec; 6(6):e00437. PubMed ID: 30410767
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.